Literature DB >> 27060052

Decline in Prostate Cancer Screening by Primary Care Physicians: An Analysis of Trends in the Use of Digital Rectal Examination and Prostate Specific Antigen Testing.

Jonathan Shoag1, Joshua A Halpern2, Daniel J Lee2, Sameer Mittal2, Karla V Ballman2, Christopher E Barbieri2, Jim C Hu2.   

Abstract

PURPOSE: Prostate cancer screening by digital rectal examination and prostate specific antigen testing has been routine clinical practice in the United States for the last 25 years. Recent studies have shown a national decline in prostate specific antigen testing following the USPSTF (United States Preventive Services Task Force) recommendation against routine prostate specific antigen screening. However, to our knowledge the effect of this recommendation on digital rectal examination utilization remains unknown.
MATERIALS AND METHODS: We used NAMCS (National Ambulatory Medical Care Survey) to characterize trends in the rate of digital rectal examination and prostate specific antigen testing by primary care physicians in men older than 40 years presenting for preventive care. From 2005 to 2012 NAMCS contained 3,368 such visits (unweighted) for the study of digital rectal examination trends and 4,035 unweighted visits from 2002 to 2012 for the study of prostate specific antigen trends.
RESULTS: Following the USPSTF recommendation the proportion of visits where digital rectal examination was performed decreased from 16.0% (95% CI 13.1-19.5) to 5.8% (95% CI 4.0-8.3, p <0.001). Similarly, the proportion of visits where prostate specific antigen testing was performed decreased from 27.3% (95% CI 24.5-30.3) to 16.7% (95% CI 12.9-21.2, p <0.001). This represents a relative 64% decrease in digital rectal examination and a 39% decrease in prostate specific antigen testing. Among men 55 to 69 years old the number of visits where digital rectal examination and prostate specific antigen testing were performed decreased 65% and 39%, respectively (p <0.001).
CONCLUSIONS: Utilization of digital rectal examination and prostate specific antigen has declined significantly following the release of the USPSTF recommendation against prostate specific antigen screening. This suggests that prostate cancer screening is rapidly disappearing from primary care practice.
Copyright © 2016 American Urological Association Education and Research, Inc. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  digital rectal examination; mass screening; practice guideline; prostate specific antigen; prostatic neoplasms

Mesh:

Substances:

Year:  2016        PMID: 27060052     DOI: 10.1016/j.juro.2016.03.171

Source DB:  PubMed          Journal:  J Urol        ISSN: 0022-5347            Impact factor:   7.450


  19 in total

1.  Prostate-specific antigen testing after the US Preventive Services Task Force recommendation: a population-based analysis of electronic health data.

Authors:  Daniel M Frendl; Mara M Epstein; Hassan Fouayzi; Richard Krajenta; Benjamin A Rybicki; Mitchell H Sokoloff
Journal:  Cancer Causes Control       Date:  2020-06-17       Impact factor: 2.506

2.  An Automated Feature Engineering for Digital Rectal Examination Documentation using Natural Language Processing.

Authors:  Selen Bozkurt; Jung In Park; Kathleen Mary Kan; Michelle Ferrari; Daniel L Rubin; James D Brooks; Tina Hernandez-Boussard
Journal:  AMIA Annu Symp Proc       Date:  2018-12-05

Review 3.  The effect of the USPSTF PSA screening recommendation on prostate cancer incidence patterns in the USA.

Authors:  Katherine Fleshner; Sigrid V Carlsson; Monique J Roobol
Journal:  Nat Rev Urol       Date:  2016-12-20       Impact factor: 14.432

Review 4.  Prostate cancer: Radiotherapy might improve survival, even in the oldest men.

Authors:  Stephen T Ryan; Jesse D Sammon
Journal:  Nat Rev Urol       Date:  2016-07-12       Impact factor: 14.432

5.  Prostate Cancer Screening and the Goldilocks Principle: How Much Is Just Right?

Authors:  Izak Faiena; Stuart Holden; Mathew R Cooperberg; Stuart Holden; Howard R Soule; Jonathan W Simons; Todd M Morgan; David F Penson; Alicia K Morgans; Maha Hussain
Journal:  J Clin Oncol       Date:  2018-02-05       Impact factor: 44.544

6.  Contemporary Incidence and Outcomes of Prostate Cancer Lymph Node Metastases.

Authors:  Adrien N Bernstein; Jonathan E Shoag; Ron Golan; Joshua A Halpern; Edward M Schaeffer; Wei-Chun Hsu; Paul L Nguyen; Art Sedrakyan; Ronald C Chen; Scott E Eggener; Jim C Hu
Journal:  J Urol       Date:  2017-12-26       Impact factor: 7.450

7.  Prostate biopsy characteristics: A comparison between pre- and post- United States Preventive Service Task Force Prostate Cancer Screening Guidelines of 2012.

Authors:  Navin Shah; Thomas Huebner; Vladimir Ioffe; Richard Hum
Journal:  Rev Urol       Date:  2017

8.  Prostate Biopsy Characteristics: A Comparison Between the Pre- and Post-2012 United States Preventive Services Task Force (USPSTF) Prostate Cancer Screening Guidelines.

Authors:  Navin Shah; Vladimir Ioffe; Thomas Huebner; Ivelina Hristova
Journal:  Rev Urol       Date:  2018

Review 9.  An update on focal therapy for prostate cancer.

Authors:  Marlon Perera; Nishanth Krishnananthan; Uri Lindner; Nathan Lawrentschuk
Journal:  Nat Rev Urol       Date:  2016-09-27       Impact factor: 14.432

10.  Prostate-specific antigen testing for prostate cancer screening: A national survey of Canadian primary care physicians' opinions and practices.

Authors:  Mitchell Geoffrey Goldenberg; Sean C Skeldon; Madhur Nayan; Yegappan Suppiah; Linda Chow; Elise Fryml; David Greenberg; Rajiv K Singal; S Larry Goldenberg
Journal:  Can Urol Assoc J       Date:  2017-11-01       Impact factor: 1.862

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.